Targeted Cancer Therapies
Precision medicine revolutionizing how we treat cancer
This journey emerged from 27 new research articles across Medicine and Interdisciplinary.
This topic surfaced automatically because research activity is surging — up +69% versus its 12-week baseline, across multiple disciplines.
Modern cancer treatment is shifting from one-size-fits-all chemotherapy to precision approaches that target specific molecular vulnerabilities in tumors. Recent breakthroughs show how identifying genetic mutations like EGFR and HER2 in lung cancer patients enables doctors to select drugs that dramatically extend survival by attacking cancer cells while sparing healthy tissue. This personalized approach represents a fundamental transformation in oncology.
Multiple recent trials demonstrate that targeted therapies are doubling survival times for patients with specific lung cancer mutations, offering hope where traditional treatments have failed. As researchers identify more molecular targets and develop corresponding drugs, clinical trials become essential proving grounds for these life-extending treatments. The success of these precision approaches is reshaping cancer care and accelerating the pace of therapeutic innovation.
The learning journey
Clinical trial
Understanding how new treatments are rigorously tested
Targeted therapy
How precision drugs attack specific cancer vulnerabilities
Medical ethics
Balancing innovation, patient access, and trial design
Current research
See the latest discoveries driving this topic below.
Foundational explainers
Research timeline in this topic
Open questions
Science still doesn't fully know:
- How can we identify which patients will respond to targeted therapies before treatment begins?
- Why do some cancers develop resistance to targeted drugs over time, and can we prevent this?
- What combination strategies will overcome tumor heterogeneity where different cells harbor different mutations?
Continue exploring